Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer

BACKGROUND: We assess the prognostic value of chemotherapy-induced leukopenia and sensory neuropathy in the CALYPSO trial patients treated with carboplatin–paclitaxel (CP) or carboplatin–liposomal doxorubicin (CPLD). METHODS: We performed a landmark analysis at first month after randomisation to cor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Lee, C K, Gurney, H, Brown, C, Sorio, R, Donadello, N, Tulunay, G, Meier, W, Bacon, M, Maenpaa, J, Petru, E, Reed, N, Gebski, V, Pujade-Lauraine, E, Lord, S, Simes, R J, Friedlander, M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2011
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3172911/
https://ncbi.nlm.nih.gov/pubmed/21750553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2011.256
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares